-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 N8RWATvpLTVm1IYXbfQfMnFEqWuz9VxF5qB1cmvYcYtq3pnLsGFHIbrjQAbEPdJu
 CO/tmujg9YRVfUz9e7TBNA==

<SEC-DOCUMENT>0001325310-09-000034.txt : 20090617
<SEC-HEADER>0001325310-09-000034.hdr.sgml : 20090617
<ACCEPTANCE-DATETIME>20090616200109
ACCESSION NUMBER:		0001325310-09-000034
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20090605
FILED AS OF DATE:		20090617
DATE AS OF CHANGE:		20090616

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ALDA Pharmaceuticals Corp.
		CENTRAL INDEX KEY:			0001355736
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			A1
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51848
		FILM NUMBER:		09895190

	BUSINESS ADDRESS:	
		STREET 1:		635 COLUMBIA STREET
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V6E1T9
		BUSINESS PHONE:		6045218300

	MAIL ADDRESS:	
		STREET 1:		635 COLUMBIA STREET
		CITY:			VANCOUVER
		STATE:			A1
		ZIP:			V6E1T9
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6k090605news.htm
<DESCRIPTION>NEWS RELEASE AND MCR ANNOUNCING OPTION GRANT
<TEXT>
<HTML>
<head><title>OMB APPROVAL</title></head><body style="FONT-SIZE:10pt; COLOR:#000000; LINE-HEIGHT:12pt; FONT-FAMILY:Times New Roman">
<div style=WIDTH:864px><p style=MARGIN:0px><br></p><table style=FONT-SIZE:10pt cellspacing=0><tr height=0 style=FONT-SIZE:0px>
<td width=663 /><td width=184 /></tr><tr><td width=663 style="BORDER-RIGHT:#000000 1px solid" valign=top>
<p>&nbsp;</p></td><td width=184 style="BORDER-RIGHT:#000000 1px solid; BORDER-TOP:#000000 1px solid; BORDER-BOTTOM:#000000 1px solid" valign=top>
<p style="MARGIN-TOP:1px; FONT-SIZE:8pt; MARGIN-BOTTOM:0px; LINE-HEIGHT:10pt; FONT-FAMILY:Arial" align=center>OMB APPROVAL</p></td></tr>
<tr><td width=663 style="BORDER-RIGHT:#000000 1px solid" valign=top><p>&nbsp;</p></td><td width=184 style="BORDER-RIGHT:#000000 1px solid; BORDER-BOTTOM:#000000 1px solid" valign=top>
<p style="MARGIN-TOP:1px; FONT-SIZE:8pt; MARGIN-BOTTOM:0px; LINE-HEIGHT:10pt; FONT-FAMILY:Arial" align=right>OMB Number: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3235-0116
<br>Expires: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;March 31, 2011
<br>Estimated average burden &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<font style="COLOR:#ffffff; BACKGROUND-COLOR:#ffffff">.
<br></font>hours per response &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.7</p></td></tr></table>
<p style=MARGIN:0px><br></p><p style="FONT-SIZE:16pt; MARGIN:0px; LINE-HEIGHT:18pt" align=center><b>UNITED STATES</b></p>
<p style="FONT-SIZE:16pt; MARGIN:0px; LINE-HEIGHT:18pt" align=center><b>SECURITIES AND EXCHANGE COMMISSION</b></p>
<p style="FONT-SIZE:16pt; MARGIN:0px; LINE-HEIGHT:18pt" align=center><b>Washington, D.C. 20549</b></p>
<p style=MARGIN:0px align=center><br></p><p style="FONT-SIZE:14pt; MARGIN:0px; LINE-HEIGHT:16pt" align=center>
<b>Form 6-K</b></p><p style=MARGIN:0px align=center><br></p><p style=MARGIN:0px align=center><b>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</b></p>
<p style=MARGIN:0px><br></p><p style=MARGIN:0px>For the month of <b><u>&nbsp;JUNE 2009</u></b></p><p style=MARGIN:0px>
<br></p><p style=MARGIN:0px>Commission File Number: <b><u>51848</u></b></p><p style=MARGIN:0px align=center>
<br></p><p style="FONT-SIZE:11pt; MARGIN:0px; LINE-HEIGHT:13pt" align=center><b><u>ALDA Pharmaceuticals Corp.</u></b></p>
<p style=MARGIN:0px align=center>(Translation of registrant&#146;s name into English)</p><p style="MARGIN-TOP:6px; FONT-SIZE:11pt; MARGIN-BOTTOM:0px; LINE-HEIGHT:13pt" align=center>
<b><u>635 Columbia St. New Westminster, B.C., Canada, V3M 1A7</u></b></p><p style=MARGIN:0px align=center>(Address of principal executive office)</p>
<p style=MARGIN:0px><br></p><p style=MARGIN:0px>Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</p>
<p style=MARGIN:0px>Form 20-F [X]<font style=FONT-FAMILY:Arial>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font>&nbsp;Form 40-F
<font style=FONT-FAMILY:Arial>&#56256;&#56453;</font></p><p style=MARGIN:0px><br></p><p style=MARGIN:0px>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____</p>
<p style=MARGIN:0px><br></p><p style=MARGIN:0px><b>Note</b>: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.</p>
<p style=MARGIN:0px><br></p><p style=MARGIN:0px>Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____</p>
<p style=MARGIN:0px><br></p><p style=MARGIN:0px align=justify><b>Note: </b>Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home country exchange on which the registrant&#146;s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant&#146;s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.</p>
<p style=MARGIN:0px><br></p><p style=MARGIN:0px>Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. </p>
<p style=MARGIN:0px><br><br></p><p style="PAGE-BREAK-BEFORE:always; MARGIN:0px">Yes <font style=FONT-FAMILY:Arial>&#56256;&#56453;</font>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No [X]</p>
<p style=MARGIN:0px><br></p><p style=MARGIN:0px>If &#147;Yes&#148; is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): &nbsp;&nbsp;82-_______________.</p>
<p style=MARGIN:0px align=center><br></p><table style=FONT-SIZE:10pt cellspacing=0><tr height=0 style=FONT-SIZE:0px>
<td width=80 /><td width=539 /></tr><tr><td width=80 valign=top><p style=MARGIN:0px><b><u>Exhibit No.</u></b></p></td>
<td width=539 valign=top><p style=MARGIN:0px><b><u>Document</u></b></p></td></tr><tr><td width=80><p style="MARGIN-TOP:0px; MARGIN-BOTTOM:5px" align=center>1</p></td>
<td width=539><p style="MARGIN-TOP:0px; MARGIN-BOTTOM:5px; COLOR:#0000ff"><a href=#news><u>June 5,<a name=_Hlt231104368 />
<a name=_Hlt231104369 />2009 News Rel<a name=_Hlt228077552 /><a name=_Hlt228077553 />ease &#150; Option Grant</u></a></p></td></tr>
<tr><td width=80><p style="MARGIN-TOP:0px; MARGIN-BOTTOM:5px" align=center>2</p></td><td width=539><p style="MARGIN-TOP:0px; MARGIN-BOTTOM:5px; COLOR:#0000ff">
<a href=#mcr><u>June 16, 2009 Material Change Report &#150; Option Grant</u></a></p></td></tr></table>
<p style=MARGIN:0px><br></p><p style=MARGIN:0px align=center><br></p><p style=MARGIN:0px align=center>
<b>SIGNATURES</b></p><p style=MARGIN:0px><br></p><p style=MARGIN:0px>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p>
<p style=MARGIN:0px><br></p><p style="FONT-SIZE:11pt; MARGIN:0px; TEXT-INDENT:384px; LINE-HEIGHT:normal">
<b>ALDA Pharmaceuticals Corp.</b><font style=FONT-SIZE:10pt></font></p><p style=MARGIN:0px>Date:<u>June 16, 2009 &nbsp;&nbsp;&nbsp;</u></p>
<p style="MARGIN-TOP:0px; MARGIN-BOTTOM:-16px; TEXT-INDENT:360px">By: </p><p style="MARGIN:0px; TEXT-INDENT:408px">&#147;
<font style=COLOR:#00007f><b><i>Terrance G. Owen</i></b></font>&#148;</p><p style=MARGIN:0px><br></p>
<p style="MARGIN-TOP:0px; MARGIN-BOTTOM:-16px">&nbsp;&nbsp;</p><p style="MARGIN-TOP:0px; MARGIN-BOTTOM:-16px; TEXT-INDENT:360px">Name:</p>
<p style="MARGIN:0px; TEXT-INDENT:408px">Terrance G. Owen, Ph.D., M.B.A.</p><p style="MARGIN-TOP:0px; MARGIN-BOTTOM:-26px; TEXT-INDENT:360px; LINE-HEIGHT:20pt">Title: </p>
<p style="MARGIN:0px; TEXT-INDENT:408px; LINE-HEIGHT:18pt">President & CEO</p><p style="PADDING-BOTTOM:4px; MARGIN:0px; LINE-HEIGHT:18pt; BORDER-BOTTOM:#000000 4px groove">
<br></p><p style="MARGIN:0px; LINE-HEIGHT:18pt"><br></p><p style="MARGIN:0px; LINE-HEIGHT:18pt"><br></p>
<p style="MARGIN-TOP:0px; MARGIN-BOTTOM:8px; LINE-HEIGHT:18.6pt" align=center><br></p><p style="MARGIN-TOP:0px; FONT-SIZE:16pt; MARGIN-BOTTOM:8px; PAGE-BREAK-BEFORE:always; LINE-HEIGHT:18.6pt" align=center>
<b>ALDA PHARMACEUTICALS CORP</b><font style=FONT-SIZE:12pt><b>.</b></font></p><p style="FONT-SIZE:11pt; MARGIN:0px; LINE-HEIGHT:12.6pt" align=center>
<b>635 Columbia Street<br>New Westminster, British Columbia V3M 1A7</b></p><p style="FONT-SIZE:11pt; MARGIN:0px; LINE-HEIGHT:18.5pt" align=center>
<b>Tel: (604) 521-8300 Fax: (604) 521-8322</b></p><p style="FONT-SIZE:14pt; MARGIN:0px; LINE-HEIGHT:16pt" align=center>
<b>NEWS RELEASE</b></p><p style="FONT-SIZE:11pt; MARGIN:0px; LINE-HEIGHT:13pt" align=right><b>TSX-V: APH</b></p>
<p style="FONT-SIZE:11pt; MARGIN:0px; LINE-HEIGHT:normal" align=right><b>OTCBB:</b><font style=FONT-SIZE:12pt>
<b>APCSF</b></font></p><p style=MARGIN:0px align=center><br></p><a name=news /><p style="FONT-SIZE:14pt; PADDING-BOTTOM:4px; MARGIN:0px; LINE-HEIGHT:16pt; BORDER-BOTTOM:#000000 1px solid" align=center>
<b>ALDA Grants Incentive Stock Options</b></p><p style=MARGIN:0px><br></p><p style=MARGIN:0px align=justify>
<b>June 5, 2009 - Vancouver, BC - ALDA Pharmaceuticals Corp.</b>(APH:TSX-V, &#147;ALDA&#148;)<b></b>announces that it has granted incentive stock options to certain directors, senior officers, employees and consultants to purchase an aggregate of 1,600,000 common shares at an exercise price of $0.25 and a term of five years, expiring on June 4, 2014. &nbsp;The options and shares issuable upon exercise, if any, will be subject to a four-month hold period from the date of grant in accordance with TSX Venture Exchange policy. &nbsp;The grant was pursuant to the Company's Rolling Stock Option Plan, which was re-affirmed by the shareholders of the Company on December 12, 2008 and subsequently accepted by the Exchange. The total number of options outstanding after this grant will be 5,120,000.. </p>
<p style=MARGIN:0px><br></p><p style=MARGIN:0px><b><u>About ALDA Pharmaceuticals Corp.</u></b></p><p style=MARGIN:0px>ALDA is focused on the development of infection-control therapeutics derived from its patented T
<sup>3</sup>6<sup>&#174;</sup>technology. The Company trades on the TSX Venture Exchange under the symbol APH and on the OTC BB under the symbol APCSF.</p>
<p style=MARGIN:0px><br></p><p style=MARGIN:0px><b>Terrance G. Owen</b>, Ph.D., MBA</p><p style="PADDING-RIGHT:268px; MARGIN:0px">President, CEO and Director
<br>ALDA Pharmaceuticals Corp.</p><p style="PADDING-RIGHT:268px; MARGIN:0px; COLOR:#0000ff"><b><i><u>www.aldacor
<a name=_Hlt115846424 />p.com</u></i></b></p><p style=MARGIN:0px><br></p><p style="PADDING-RIGHT:268px; MARGIN:0px">
<b><i><u>Distribution & Sales Contact<br></u></i>Diane Mann</b></p><p style="PADDING-RIGHT:268px; MARGIN:0px">(604) &nbsp;521-8300 Ext. 4</p>
<p style="MARGIN:0px; COLOR:#0000ff"><b><i><u>diane_mann@aldacorp.com<br></u></i></b></p><p style="PADDING-RIGHT:268px; MARGIN:0px">
<b><i><u /></i></b>&nbsp;</p><p style="PADDING-RIGHT:268px; MARGIN:0px"><b><i><u>Retail Sales</u></i></b></p>
<p style=MARGIN:0px>Eastern Esthetics (ON, QU, NB, NS, PE, NL) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(902) 450-2161</p>
<p style=MARGIN:0px>LCN Canada &#150; West (MB, SK, AB, BC, NW, YK) &nbsp;&nbsp;(780) 462-2580</p><p style=MARGIN:0px>
<br></p><p style="PADDING-RIGHT:268px; MARGIN:0px"><b><i><u>Investor Relations Contact</u></i></b></p>
<p style="PADDING-RIGHT:268px; MARGIN:0px"><b>Scott Young</b></p><p style=MARGIN:0px>(604) 288-7222</p>
<p style="MARGIN:0px; COLOR:#0000ff"><b><i><u>syoung@freeformcom.com</u></i></b><font style=COLOR:#000000></font></p>
<p style="MARGIN:0px; LINE-HEIGHT:12.6pt"><br></p><p style=MARGIN:0px><i>Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.</i></p>
<p style=MARGIN:0px><br></p><p style=MARGIN:0px><br><br></p><p style="PAGE-BREAK-BEFORE:always; MARGIN:0px" align=justify>
<i>Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves ALDA&#146;s expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. ALDA generally uses words such as &#147;outlook,&#148; &#147;will,&#148; &#147;could,&#148; &#147;would,&#148; &#147;might,&#148; &#147;remains,&#148; &#147;to be,&#148; &#147;plans,&#148; &#147;believes,&#148; &#147;may,&#148; &#147;expects,&#148; &#147;intends,&#148; &#147;anticipates,&#148; &#147;estimate,&#148; &#147;future,&#148; &#147;plan,&#148; &#147;positioned,&#148; &#147;potential,&#148; &#147;project,&#148; &#147;remain,&#148; &#147;scheduled,&#148; &#147;set to,&#148; &#147;subject to,&#148; &#147;upcoming,&#148; and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to ALDA as of the date of this release, and ALDA assume
s no obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of ALDA and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.</i></p>
<p style="MARGIN:0px; LINE-HEIGHT:12.6pt"><br></p><p style=MARGIN:0px><br></p><p style=MARGIN:0px><br></p>
<p style=MARGIN:0px><br></p><p style=MARGIN:0px><br></p><p style="PADDING-BOTTOM:4px; MARGIN:0px; BORDER-BOTTOM:#000000 2px solid">
<br></p><p style=MARGIN:0px><br></p><p style=MARGIN:0px><br></p><p style=MARGIN:0px><br></p><p style=MARGIN:0px>
<br></p><p style=MARGIN:0px><br></p><p style=MARGIN:0px><br></p><p style=MARGIN:0px><br></p><p style=MARGIN:0px>
<br></p><p style=MARGIN:0px><br></p><p style=MARGIN:0px align=center><br><br></p><p style="FONT-SIZE:14pt; PAGE-BREAK-BEFORE:always; MARGIN:0px; LINE-HEIGHT:16pt" align=center>
<b>Form 51-102F3</b></p><p style=MARGIN:0px align=center><br></p><a name=mcr /><p style="FONT-SIZE:11pt; MARGIN:0px; LINE-HEIGHT:13pt" align=center>
<b>MATERIAL CHANGE REPORT</b></p><p style=MARGIN:0px><br></p><p style="MARGIN-TOP:0px; MARGIN-BOTTOM:-16px" align=justify>
<b>Item 1 </b></p><p style="MARGIN:0px; TEXT-INDENT:72px" align=justify><b>Name and Address of Company</b></p>
<p style=MARGIN:0px><br></p><p style="PADDING-LEFT:72px; MARGIN:0px" align=justify><b>ALDA PHARMACEUTICALS CORP. </b></p>
<p style="PADDING-LEFT:72px; MARGIN:0px" align=justify>("ALDA" or the &#147;Company&#148;)</p><p style="PADDING-LEFT:72px; MARGIN:0px">635 Columbia Street</p>
<p style="PADDING-LEFT:72px; MARGIN:0px">New Westminster, BC V3M 1A7</p><p style=MARGIN:0px align=justify>
<br></p><p style="MARGIN-TOP:0px; MARGIN-BOTTOM:-16px" align=justify><b>Item 2 </b></p><p style="MARGIN:0px; TEXT-INDENT:72px" align=justify>
<b>Date of Material Change</b></p><p style=MARGIN:0px align=justify><br></p><p style="PADDING-LEFT:96px; MARGIN:0px; TEXT-INDENT:-24px" align=justify>June 5, 2009</p>
<p style=MARGIN:0px align=justify><br></p><p style="MARGIN-TOP:0px; MARGIN-BOTTOM:-16px" align=justify>
<b>Item 3 </b></p><p style="MARGIN:0px; TEXT-INDENT:72px" align=justify><b>News Release</b></p><p style=MARGIN:0px align=justify>
<br></p><p style="PADDING-LEFT:96px; MARGIN:0px; TEXT-INDENT:-24px">A news release was issued on June 5, 2009, at Vancouver, BC</p>
<p style=MARGIN:0px align=justify><br></p><p style="MARGIN-TOP:0px; MARGIN-BOTTOM:-16px" align=justify>
<b>Item 4 </b></p><p style="MARGIN:0px; TEXT-INDENT:72px" align=justify><b>Summary of Material Change</b></p>
<p style=MARGIN:0px><br></p><p style="PADDING-LEFT:72px; MARGIN:0px" align=justify>ALDA has granted incentive stock options to certain directors, senior officers, employees and consultants to purchase an aggregate of 1,600,000 common shares.</p>
<p style=MARGIN:0px><br></p><p style="MARGIN-TOP:0px; MARGIN-BOTTOM:-16px" align=justify><b>Item 5 </b></p>
<p style="MARGIN:0px; TEXT-INDENT:72px" align=justify><b>Full Description of Material Change</b></p><p style=MARGIN:0px>
<br></p><p style="PADDING-LEFT:72px; MARGIN:0px" align=justify>ALDA has granted incentive stock options to certain directors, senior officers, employees and consultants to purchase an aggregate of 1,600,000 common shares at an exercise price of $0.25 and a term of five years, expiring on June 4, 2014. &nbsp;The options and shares issuable upon exercise, if any, will be subject to a four-month hold period from the date of grant in accordance with TSX Venture Exchange policy. &nbsp;The grant was pursuant to the Company's Rolling Stock Option Plan, which was re-affirmed by the shareholders of the Company on December 12, 2008 and subsequently accepted by the Exchange. The total number of options outstanding after this grant will be 5,120,000. </p>
<p style=MARGIN:0px><br></p><p style="MARGIN-TOP:0px; MARGIN-BOTTOM:-16px" align=justify><b>Item 6 </b></p>
<p style="MARGIN:0px; TEXT-INDENT:72px" align=justify><b>Reliance on subsection 7.1(2) or (3) of National Instrument 51-102</b></p>
<p style=MARGIN:0px align=justify><br></p><p style="PADDING-LEFT:96px; MARGIN:0px; TEXT-INDENT:-24px" align=justify>Not applicable.</p>
<p style=MARGIN:0px align=justify><br></p><p style="MARGIN-TOP:0px; MARGIN-BOTTOM:-16px" align=justify>
<b>Item 7 </b></p><p style="MARGIN:0px; TEXT-INDENT:72px" align=justify><b>Omitted Information</b></p>
<p style=MARGIN:0px align=justify><br></p><p style="PADDING-LEFT:96px; MARGIN:0px; TEXT-INDENT:-24px" align=justify>Not applicable.</p>
<p style=MARGIN:0px align=justify><br></p><p style="MARGIN-TOP:0px; MARGIN-BOTTOM:-16px" align=justify>
<b>Item 8 </b></p><p style="MARGIN:0px; TEXT-INDENT:72px" align=justify><b>Executive Officer</b></p><p style=MARGIN:0px>
<br></p><p style="PADDING-LEFT:72px; MARGIN:0px">Terrance G. Owen, Ph.D., MBA, President & CEO at (604) 521-8300</p>
<p style=MARGIN:0px /><p style="PAGE-BREAK-BEFORE:always; MARGIN:0px" align=justify><br></p><p style="MARGIN-TOP:0px; MARGIN-BOTTOM:-16px" align=justify>
<b>Item 9 </b></p><p style="MARGIN:0px; TEXT-INDENT:72px" align=justify><b>Date of Report</b></p><p style=MARGIN:0px>
<br></p><p style="PADDING-LEFT:72px; MARGIN:0px">June 16, 2009</p><p style=MARGIN:0px><br></p><p style=MARGIN:0px>
<br><br></p></div></body>
<!-- EDGAR Validation Code: D2E81B98 -->
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
